RETRACTED: Horizon scanning for novel therapeutics for the treatment of prostate cancer
Published 2010 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
RETRACTED: Horizon scanning for novel therapeutics for the treatment of prostate cancer
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 19, Issue 12, Pages 1487-1502
Publisher
Informa Healthcare
Online
2010-09-24
DOI
10.1517/13543784.2010.514261
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Longitudinal Study of Depressive Symptoms in Patients With Metastatic Gastrointestinal and Lung Cancer
- (2010) Christopher Lo et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy
- (2010) Charles J. Ryan et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer
- (2010) Daniel C. Danila et al. JOURNAL OF CLINICAL ONCOLOGY
- Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate
- (2010) Alison H.M. Reid et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
- (2010) Howard I Scher et al. LANCET
- Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer
- (2009) C. N. Sternberg et al. ANNALS OF ONCOLOGY
- Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)
- (2009) L. R. Molife et al. ANNALS OF ONCOLOGY
- A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study
- (2009) Primo N. Lara et al. ANTI-CANCER DRUGS
- Novel Agents on the Horizon for Cancer Therapy
- (2009) W. W. Ma et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862)
- (2009) Deborah Bradley et al. CANCER
- Development of Androgen Receptor Antagonists with Promising Activity in Castration-Resistant Prostate Cancer
- (2009) Howard C. Shen et al. CANCER CELL
- Antitumor Activity with CYP17 Blockade Indicates That Castration-Resistant Prostate Cancer Frequently Remains Hormone Driven
- (2009) G. Attard et al. CANCER RESEARCH
- Inhibition of the Androgen Receptor as a Novel Mechanism of Taxol Chemotherapy in Prostate Cancer
- (2009) L. Gan et al. CANCER RESEARCH
- Histone Deacetylases Are Required for Androgen Receptor Function in Hormone-Sensitive and Castrate-Resistant Prostate Cancer
- (2009) D. S. Welsbie et al. CANCER RESEARCH
- Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer
- (2009) E. Y. Yu et al. CLINICAL CANCER RESEARCH
- An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer
- (2009) G. Liu et al. CLINICAL CANCER RESEARCH
- Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer
- (2009) D. Sarker et al. CLINICAL CANCER RESEARCH
- Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors
- (2009) A. C. Mita et al. CLINICAL CANCER RESEARCH
- Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets
- (2009) Kim N. Chi et al. EUROPEAN UROLOGY
- Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors
- (2009) Quincy Siu-Chung Chu EXPERT OPINION ON BIOLOGICAL THERAPY
- New approved dasatinib regimen available for clinical use
- (2009) David S Snyder Expert Review of Anticancer Therapy
- Clusterin is a short half-life, poly-ubiquitinated protein, which controls the fate of prostate cancer cells
- (2009) Federica Rizzi et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
- (2009) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Estrogen-Progestagen Menopausal Hormone Therapy and Breast Cancer: Does Delay From Menopause Onset to Treatment Initiation Influence Risks?
- (2009) Agnès Fournier et al. JOURNAL OF CLINICAL ONCOLOGY
- Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial
- (2009) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-Term Results of a Randomized Trial of Surgery With or Without Preoperative Chemotherapy in Esophageal Cancer
- (2009) William H. Allum et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data
- (2009) Howard I Scher et al. LANCET ONCOLOGY
- Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target
- (2009) Yu Chen et al. LANCET ONCOLOGY
- Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer
- (2009) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions
- (2009) A Gualberto et al. ONCOGENE
- Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience
- (2008) D. Olmos et al. ANNALS OF ONCOLOGY
- The TGF-β, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer
- (2008) Stephen J. Assinder et al. BIOCHEMICAL JOURNAL
- Molecular requirements for induction of CTGF expression by TGF-β1 in primary osteoblasts
- (2008) J.A. Arnott et al. BONE
- Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer
- (2008) G Attard et al. BRITISH JOURNAL OF CANCER
- Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer
- (2008) Celestia S. Higano et al. CANCER
- Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer
- (2008) Joel B. Nelson et al. CANCER
- Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy
- (2008) Jennifer S. Carew et al. CANCER LETTERS
- Enhancing Mammalian Target of Rapamycin (mTOR)-Targeted Cancer Therapy by Preventing mTOR/Raptor Inhibition-Initiated, mTOR/Rictor-Independent Akt Activation
- (2008) X. Wang et al. CANCER RESEARCH
- Tenets of PTEN Tumor Suppression
- (2008) Leonardo Salmena et al. CELL
- Microtubule Active Agents: Beyond the Taxane Frontier
- (2008) P. G. Morris et al. CLINICAL CANCER RESEARCH
- A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer
- (2008) E. I. Heath et al. CLINICAL CANCER RESEARCH
- Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
- (2008) J. S. de Bono et al. CLINICAL CANCER RESEARCH
- Heat Shock Protein 90 as a Drug Target: Some Like It Hot
- (2008) U. Banerji CLINICAL CANCER RESEARCH
- Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study
- (2008) Giuseppe Di Lorenzo et al. EUROPEAN UROLOGY
- Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial
- (2008) Nicholas D. James et al. EUROPEAN UROLOGY
- Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer
- (2008) Mari Björkman et al. INTERNATIONAL JOURNAL OF CANCER
- Clusterin is epigenetically regulated in prostate cancer
- (2008) Hanna E. Rauhala et al. INTERNATIONAL JOURNAL OF CANCER
- Targeting Polo-Like Kinase: Learning Too Little Too Late?
- (2008) David Olmos et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors
- (2008) Anne O'Donnell et al. JOURNAL OF CLINICAL ONCOLOGY
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
- (2008) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Dissecting prostate carcinogenesis through ETS gene rearrangement studies: implications for anticancer drug development
- (2008) G Attard et al. JOURNAL OF CLINICAL PATHOLOGY
- Epothilones: tubulin polymerization as a novel target for prostate cancer therapy
- (2008) James J Lee et al. Nature clinical practice. Oncology
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started